DGAP-News 599 0 Kommentare Epigenomics AG announces 2017 First Quarter Financial Results - Seite 2

- Epigenomics Joins Forces with "80% by 2018" initiative: Epigenomics has made the pledge to help increase colorectal cancer screening rates by supporting the 80% by 2018 initiative, led by the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC) and the National Colorectal Cancer Roundtable (a coalition co-founded by ACS and CDC). "80% by 2018" is a shared goal to have 80% of adults aged 50 and older screened for colorectal cancer by 2018.

- ADMIT study results published: The Journal of "Cancer Treatment and Research Communications" published results of the ADMIT trial (ADherence to Minimally Invasive Testing) with Epi proColon. Study results confirm that a blood-based colorectal cancer screening test has the potential to increase the participation in colorectal cancer screening compared to a fecal test. The study demonstrated a 99.5% rate of adherence to CRC screening using Epi proColon.

- Systematic study review for Epi proColon published: Scientific results of a recent systematic review and meta-analysis of clinical studies with Epi proColon were published in "Clinical and Translational Gastroenterology", a journal of the Nature Publishing Group. After analyzing results from 25 independent studies from different geographical areas, the authors conclude that methylated Septin 9 detected by the Epi proColon test "is a reliable blood-based marker in colorectal cancer detection".

- Publication in Journal of Molecular Diagnosis & Therapy: An independent, peer-reviewed article on the blood-based colorectal cancer screening test Epi proColon 2.0 CE was published in the Journal of Molecular Diagnosis & Therapy. According to the study authors Yvette N. Lamb and Sohita Dhillon, Epi proColon(R) 2.0 CE demonstrated high sensitivity and specificity in case control studies. Furthermore, it provides a patient-friendly option that may increase participation in colorectal cancer screening programs.

Outlook 2017 confirmed

The Company confirms the outlook for the financial year 2017 as provided on April 26, 2017.

Further Information